Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMRNASDAQ:ONCONASDAQ:VALNNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$2.89+0.3%$2.24$1.61▼$11.20$185.04M0.79812,756 shs411,566 shsONCOOnconetix$4.26-9.9%$6.08$4.05▼$1,190.00$3.60M3.5103,913 shs228,841 shsVALNValneva$6.07+1.2%$6.46$3.62▼$8.66$516.52M1.8142,591 shs31,348 shsVERVVerve Therapeutics$6.27+1.8%$4.86$2.86▼$11.15$558.93M1.671.98 million shs2.21 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics0.00%+7.46%+45.45%+12.94%-69.33%ONCOOnconetix0.00%-24.90%-34.30%-55.84%-99.02%VALNValneva0.00%-2.26%-4.83%-11.75%-17.10%VERVVerve Therapeutics0.00%-0.65%+33.05%-2.53%+13.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLRMRLarimar Therapeutics2.4161 of 5 stars3.63.00.00.02.81.70.0ONCOOnconetix0.3375 of 5 stars0.04.00.00.01.90.00.0VALNValneva2.6642 of 5 stars3.55.00.00.02.60.80.0VERVVerve Therapeutics2.4514 of 5 stars3.51.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.11Buy$19.67580.51% UpsideONCOOnconetix 0.00N/AN/AN/AVALNValneva 3.00Buy$15.50155.35% UpsideVERVVerve Therapeutics 3.00Buy$25.75310.69% UpsideCurrent Analyst Ratings BreakdownLatest ONCO, VERV, LRMR, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/AONCOOnconetix$1.93M1.69N/AN/A$3.01 per share1.42VALNValneva$186.06M2.78N/AN/A$2.00 per share3.04VERVVerve Therapeutics$59.61M9.38N/AN/A$7.31 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)ONCOOnconetix-$37.41MN/A0.00∞N/A-2,758.89%N/A-48.09%8/27/2025 (Estimated)VALNValneva-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)Latest ONCO, VERV, LRMR, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 million5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/A3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A13.1013.10ONCOOnconetixN/A0.060.05VALNValneva0.702.782.25VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%ONCOOnconetix23.89%VALNValneva11.39%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%ONCOOnconetix3.10%VALNValneva14.91%VERVVerve Therapeutics19.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableONCOOnconetix12762,00057.17 millionN/AVALNValneva70085.09 million69.15 millionNot OptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableONCO, VERV, LRMR, and VALN HeadlinesRecent News About These CompaniesEli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reportsJune 16 at 7:49 PM | reuters.comVerve Therapeutics’ SWOT analysis: gene editing stock shows promise amid challengesJune 15 at 10:48 AM | investing.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Down - Here's What HappenedJune 15 at 3:45 AM | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Down - Should You Sell?June 13 at 1:03 PM | marketbeat.comWhat Makes Verve Therapeutics (VERV) a New Buy StockJune 13 at 1:01 PM | zacks.comVerve Therapeutics reports voting results from annual meetingJune 11, 2025 | investing.comBrokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $25.75June 11, 2025 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up - What's Next?June 9, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Buy" by AnalystsJune 8, 2025 | marketbeat.comVerve Therapeutics (VERV) Just Reclaimed the 200-Day Moving AverageJune 6, 2025 | zacks.comVerve Therapeutics (NASDAQ:VERV) Trading 10.1% Higher - Time to Buy?June 5, 2025 | marketbeat.comWall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?June 5, 2025 | zacks.comPublic Employees Retirement System of Ohio Purchases 47,656 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)June 5, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comBank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Has $1.65 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Two Sigma Investments LPMay 31, 2025 | marketbeat.comNuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 31, 2025 | marketbeat.comHeart Disease Could Be a Goner When These New Drugs ArriveMay 29, 2025 | msn.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comExperimental drug promising to bring down bad cholesterol by up to 69% completes early stage trialMay 26, 2025 | theprint.inNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCO, VERV, LRMR, and VALN Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$2.89 +0.01 (+0.35%) Closing price 04:00 PM EasternExtended Trading$2.83 -0.06 (-2.04%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Onconetix NASDAQ:ONCO$4.26 -0.47 (-9.94%) Closing price 04:00 PM EasternExtended Trading$4.30 +0.04 (+1.06%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Valneva NASDAQ:VALN$6.07 +0.07 (+1.17%) Closing price 03:59 PM EasternExtended Trading$6.12 +0.05 (+0.81%) As of 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Verve Therapeutics NASDAQ:VERV$6.27 +0.11 (+1.79%) Closing price 04:00 PM EasternExtended Trading$10.97 +4.70 (+75.02%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
